Skip to main content

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Publication ,  Journal Article
Baselga, J; Cervantes, A; Martinelli, E; Chirivella, I; Hoekman, K; Hurwitz, HI; Jodrell, DI; Hamberg, P; Casado, E; Elvin, P; Swaisland, A ...
Published in: Clin Cancer Res
October 1, 2010

PURPOSE: This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with advanced solid malignancies. Tumor biopsy samples were taken to investigate the effect of saracatinib on Src activity in tumors. EXPERIMENTAL DESIGN: Part A of the study followed a multiple-ascending dose design to establish the maximum tolerated dose (MTD) of saracatinib. Part B was a randomized, parallel-group, cohort-expansion phase to further assess tolerated doses. Safety, tolerability, and Src activity (immunohistochemistry and lysate-based methodologies) were assessed after 21 days of once-daily oral dosing. PK was assessed after single and multiple dosing. RESULTS: In part A, 30 patients received once-daily saracatinib at doses of 60 to 250 mg; the MTD was established as 175 mg. In part B, 51 patients were randomized to receive 50 mg (n = 16), 125 mg (n = 16), or 175 mg (n = 19) of saracatinib. The most common grade ≥3 events considered to be treatment related were anemia, diarrhea, and asthenia. Tumor Src activity was reduced following saracatinib treatment. The area under the concentration-time curve and C(max) of saracatinib increased with increasing dose. Saracatinib accumulated 4- to 5-fold on once-daily dosing to reach steady-state exposure after 10 to 17 days of dosing. The half-life was ∼40 hours. CONCLUSIONS: Saracatinib was well tolerated in patients with advanced solid malignancies. A reduction in tumor Src activity was observed. PK data show that saracatinib is suitable for once-daily oral dosing. Based on this study, the recommended dose for the phase II studies was chosen to be 175 mg/d.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

October 1, 2010

Volume

16

Issue

19

Start / End Page

4876 / 4883

Location

United States

Related Subject Headings

  • src-Family Kinases
  • Young Adult
  • Treatment Outcome
  • Quinazolines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Baselga, J., Cervantes, A., Martinelli, E., Chirivella, I., Hoekman, K., Hurwitz, H. I., … Tabernero, J. (2010). Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res, 16(19), 4876–4883. https://doi.org/10.1158/1078-0432.CCR-10-0748
Baselga, José, Andres Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, et al. “Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.Clin Cancer Res 16, no. 19 (October 1, 2010): 4876–83. https://doi.org/10.1158/1078-0432.CCR-10-0748.
Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, et al. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res. 2010 Oct 1;16(19):4876–83.
Baselga, José, et al. “Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.Clin Cancer Res, vol. 16, no. 19, Oct. 2010, pp. 4876–83. Pubmed, doi:10.1158/1078-0432.CCR-10-0748.
Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res. 2010 Oct 1;16(19):4876–4883.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

October 1, 2010

Volume

16

Issue

19

Start / End Page

4876 / 4883

Location

United States

Related Subject Headings

  • src-Family Kinases
  • Young Adult
  • Treatment Outcome
  • Quinazolines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Maximum Tolerated Dose
  • Male